Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium hyaluronate + amino acids is a combination ophthalmic solution designed for the treatment of dry eye syndrome and the promotion of ocular surface recovery following surgery, such as cataract extraction. Sodium hyaluronate, a high-molecular-weight glycosaminoglycan, acts as a potent lubricant and humectant that stabilizes the tear film and protects the corneal endothelium. The amino acid component—typically consisting of glycine, L-proline, L-lysine, and L-leucine—serves as a nutritional substrate for the corneal epithelium, supporting cellular metabolism, protein synthesis, and wound healing processes. By combining mechanical lubrication with metabolic support, the formulation helps alleviate postoperative discomfort, reduce inflammation, and accelerate the restoration of ocular surface integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + amino acids.